Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ziprasidone mesylate
Drug ID BADD_D02391
Description Disorders such as schizophrenia and bipolar disorder can significantly impair mood, cognition, and behavior.[A190525] These mental illnesses can often be accompanied by comorbidities such as depression and substance abuse, and can significantly impact the quality of life of patients and caregivers.[A190525] Luckily, several treatment options for psychotic disorders have been introduced to market since the realization of chlorpromazine's antipsychotic properties in 1952.[A190525] Second generation antipsychotics (commonly referred to as atypical antipsychotics) include [clozapine], [quetiapine], [olanzapine], [aripiprazole] and [ziprasidone] among others, and are generally thought to be as efficacious as first generation antipsychotics but differ in their adverse effect profiles.[A190525,A190534] First generation antipsychotics are associated with extrapyramidal adverse effects while atypical antipsychotics are linked to weight gain, impaired glucose tolerance and metabolic syndrome.[A190534,A190537] Ziprasidone is used to treat schizophrenia and bipolar disorder.[A180748] It can effectively reduce the rate and time of relapses in schizophrenia, and can be used to treat manic episodes in bipolar disorder although the mechanism of action is unknown.[A180748] Although ziprasidone is classified as an atypical antipsychotic, it appears to have a lower incidence of metabolic adverse effects compared to other medications in the same class.[A190525]
Indications and Usage In its oral form, ziprasidone is approved for the treatment of schizophrenia, as monotherapy for acute treatment of manic or mixed episodes related to bipolar I disorder, and as adjunctive therapy to lithium or valproate for maintenance treatment of bipolar I disorder.[L7342] The injectable formulation is approved only for treatment of acute agitation in schizophrenia.[L7342]
Marketing Status approved
ATC Code N05AE04
DrugBank ID DB00246
KEGG ID D02100
MeSH ID C092292
PubChem ID 154068
TTD Drug ID D0R1JV
NDC Product Code 0049-1203; 72266-160; 50090-4540; 51662-1564; 0049-3920; 68083-340; 72205-205; 43598-061; 43598-848
UNII 3X6SAX83JZ
Synonyms ziprasidone | ziprazidone | 5-(2-(4-(3-benzisothiazolyl)piperazinyl)ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one | ziprasidone hydrochloride | CP 88059-01 | CP-88,059-1 | CP-88,059-01 | ziprasidone hydrochloride, monohydrate | Geodon | CP 88059 | CP-88,059
Chemical Information
Molecular Formula C22H25ClN4O4S2
CAS Registry Number 185021-64-1
SMILES CS(=O)(=O)O.C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Ecchymosis23.06.01.001; 01.01.03.001; 24.07.06.002--Not Available
Eczema23.03.04.006--
Ejaculation disorder21.03.01.002--
Electrocardiogram QT prolonged13.14.05.004--
Enuresis20.02.02.003; 19.07.04.001--Not Available
Eosinophilia01.02.04.001--
Epistaxis22.04.03.001; 24.07.01.005--
Extrapyramidal disorder17.01.02.007--
Eye haemorrhage12.02.02.012; 24.07.05.002; 06.07.02.001--Not Available
Face oedema08.01.07.003; 23.04.01.004; 10.01.05.002--
Facial paralysis17.04.03.008--Not Available
Fall12.01.08.002--
Flank pain08.01.08.007; 15.03.04.003; 20.02.03.006--
Fungal skin infection23.11.03.006; 11.03.05.002--Not Available
Furuncle23.11.02.009; 11.02.05.008--Not Available
Gait disturbance15.03.05.013; 17.02.05.016; 08.01.02.002--
Galactorrhoea21.05.02.002; 05.03.04.002--Not Available
Gamma-glutamyltransferase increased13.03.04.024--
Gingival bleeding24.07.02.010; 07.09.07.001--Not Available
Glucose tolerance decreased13.02.02.004--Not Available
Glycosuria20.02.01.005--
Gout14.09.01.001; 15.01.06.001--Not Available
Gynaecomastia21.05.04.003; 05.05.02.003--
Haematemesis24.07.02.011; 07.12.02.002--Not Available
Haematuria21.10.01.018; 24.07.01.047; 20.02.01.006--
Haemoptysis02.11.04.009; 24.07.01.006; 22.02.03.004--Not Available
Headache17.14.01.001--
Heart rate increased13.14.04.002--Not Available
Hepatic steatosis14.08.04.005; 09.01.07.003--Not Available
Hepatitis09.01.07.004--Not Available
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 8 Pages